United Therapeutics Corp (NASDAQ:UTHR) currently has a daily average trading volume of 504.54K but it saw 784301 shares traded in last market. With a market cap of 13.61B USD, the company’s current market price of $303.09 came rising about 0.77 while comparing to the previous closing price of $300.76. In past 52 weeks, the stock remained buoying in the range of price level as high as $417.82 and as low as $233.31. In the recent trading on the day, stock has struck highest price mark of $293.05 while lowest mark touched by it was $319.4.
Taking a look at 20-day trading activity of United Therapeutics Corp (UTHR) gives us an average price of $291.73, while its current price level is -27.46% below from 52-week high level whereas it is 29.91% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $309.55 while that of 200 days or SMA-200 reads an average of $344.85. A closer look into the stock’s movement over the week reveals that its volatility is standing at 3.68% during that period while stretching the period over a month that increases to 4.52%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 53.84 which implies that the stock is in neutral territory.
BofA Securities upgraded its recommendation for the stock as a “Neutral” from “Underperform” on April 21, 2025 while assigning a price target of $314. Morgan Stanley also issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $310 and $321.
Over the week, UTHR’s stock price is moving 3.28% up while it is -1.68% when we observe its performance for the past one month. Year-to-date it is -14.10% down and over the past year, the stock is showing an upside performance of 29.61%.
Currently, United Therapeutics Corp’s total number of outstanding shares is 44.83M with 1.82% of that held by the insiders while 101.05% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 18.55% and return on equity (ROE) at 19.23%. It has a price to earnings ratio (P/E ratio) of 12.32 while having a 10.24 of forward P/E ratio. Stock’s beta reads 0.58. Stock has a price to book (P/B) ratio of 2.11 while price to sale or P/S ratio amounts to 4.73. Its return on asset (ROA) is 16.32% on average.
